{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T07:49:11Z","timestamp":1648540151993},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009003","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T02:43:10Z","timestamp":1512614590000},"page":"e9003","source":"Crossref","is-referenced-by-count":1,"title":["Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18"],"prefix":"10.1097","volume":"96","author":[{"given":"Yimin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhouyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-67-20210226","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"\u2019Cancer statistics in China","volume":"66","author":"Chen","year":"2015","journal-title":"CA Cancer J Clin 2016"},{"key":"R2-67-20210226","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bjc.2017.232","article-title":"Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer","volume":"117","author":"Alexander","year":"2017","journal-title":"Br J Cancer"},{"key":"R4-67-20210226","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-67-20210226","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.2013.188","article-title":"The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype","volume":"27","author":"Kadota","year":"2014","journal-title":"Mod Pathol"},{"key":"R6-67-20210226","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"R7-67-20210226","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1371\/journal.pmed.0020313","article-title":"Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants","volume":"2","author":"Greulich","year":"2005","journal-title":"PLoS Med"},{"key":"R8-67-20210226","first-page":"3885","article-title":"Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results from a multicenter retrospective study (HANSHIN Oncology Group 0212)","volume":"35","author":"Otsuka","year":"2015","journal-title":"Anticancer Res"},{"key":"R9-67-20210226","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2009","journal-title":"Lancet Oncol"},{"key":"R10-67-20210226","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","article-title":"Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer","volume":"28","author":"Sequist","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-67-20210226","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:45:17Z","timestamp":1620960317000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712080-00067"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":10,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009003","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}